Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Q9UZ
|
||||
| Former ID |
DNC013427
|
||||
| Drug Name |
2-((3-iodophenyl)(o-tolyloxy)methyl)morpholine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [528517] | ||
| Formula |
C18H20INO2
|
||||
| Canonical SMILES |
CC1=CC=CC=C1OC(C2CNCCO2)C3=CC(=CC=C3)I
|
||||
| InChI |
1S/C18H20INO2/c1-13-5-2-3-8-16(13)22-18(17-12-20-9-10-21-17)14-6-4-7-15(19)11-14/h2-8,11,17-18,20H,9-10,12H2,1H3
|
||||
| InChIKey |
GUJGIDDFMFZKIV-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Sodium-dependent noradrenaline transporter | Target Info | Inhibitor | [528517] | |
| Sodium-dependent dopamine transporter | Target Info | Inhibitor | [528517] | ||
| Pathway Interaction Database | Alpha-synuclein signaling | ||||
| WikiPathways | Monoamine Transport | ||||
| NRF2 pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP727:Monoamine Transport | |||||
| Dopaminergic Neurogenesis | |||||
| Parkinsons Disease Pathway | |||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||||
| Neurotransmitter Clearance In The Synaptic Cleft | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.